Patent: 11,078,288
✉ Email this page to a colleague
Summary for Patent: 11,078,288
| Title: | Methods and compositions for treating tumor diseases |
| Abstract: | The present invention provides, in part, methods for treating a tumor in a human subject comprising inhibiting IGF-1 receptor signaling, methods of determining whether a tumor is more or less likely to respond to such treatment, and compositions for practicing such methods. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions. |
| Inventor(s): | Beltran Pedro J., Calzone Frank J., Friberg Gregory, Haqq Christopher, Tolcher Anthony W. |
| Assignee: | Amgen Inc. |
| Application Number: | US15955304 |
| Patent Claims: | see list of patent claims |
Details for Patent 11,078,288
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Pharmacia & Upjohn Company Llc | SOMAVERT | pegvisomant | For Injection | 021106 | March 25, 2003 | ⤷ Start Trial | 2038-04-17 |
| Pharmacia & Upjohn Company Llc | SOMAVERT | pegvisomant | For Injection | 021106 | July 31, 2014 | ⤷ Start Trial | 2038-04-17 |
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | ⤷ Start Trial | 2038-04-17 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
